Biotech - Press Releases

Date	Title	Company
01-Jun-2020	Immutep announces improving data from the phase II TACTI-002 study	Immutep
01-Jun-2020	Immutep reports first results from INSIGHT-004 study	Immutep Limited
01-Jun-2020	Calliditas Therapeutics launches US IPO roadshow and targets a capital raise of MUSD 75	Calliditas Therapeutics
01-Jun-2020	Almac Clinical Technologies Introduces SimplifyTM, an Advanced IRT Solution Enabling Faster Clinical Trials Start-up	Almac Group
01-Jun-2020	Orgenesis to collaborate with The Edith Wolfson Medical Center to conduct clinical study using Orgenesis’ proprietary POCare technologies for the generation and expansion of Tumor Infiltrating Lymphocytes	Orgenesis Inc
01-Jun-2020	Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal	Kazia Therapeutics Ltd
01-Jun-2020	Mallinckrodt Will Appeal District Court Ruling in Case Involving Ongoing Acthar Medicaid Drug Rebate Dispute with the Centers for Medicare and Medicaid Services (CMS)	Mallinckrodt plc
01-Jun-2020	New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021	Oncopeptides AB
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT(R) (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT(R) (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT(R) (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies	Ascentage Pharma
30-May-2020	Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients	Guardant Health AMEA
30-May-2020	Coronavirus (COVID-19) Update: Daily Roundup	U.S. Food and Drug Administration
29-May-2020	Varian to Participate in Goldman Sachs Global Virtual Healthcare Conference	Varian